ImmuPharma PLC
("ImmuPharma" or the "Company")
AIM Rule 17 Notice
ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:
Tim McCarthy, the Company's Non-executive Chairman, is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary Liquidation.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
-Ends-
For further information please contact:
ImmuPharma plc (www.immupharma.org) |
+ 44 (0) 20 7152 4080 |
Tim McCarthy, Chairman |
|
Lisa Baderoon, Head of Investor Relations [email protected] Twitter: @immupharma |
+ 44 (0) 7721 413496 |
Northland Capital Partners Limited (NOMAD & Broker) David Hignell, Dugald J. Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking |
+44 (0)20 3861 6625 |
|
|
|
|
|
|
|
|
